Close Menu

rheumatic diseases

Despite the diversity detected in Group A Streptococcus strains from more than 20 countries, investigators narrowed in on broadly shared sequences with relatively low variation.

The company said this week that is has raised $36 million in funding, as it continues efforts to develop its Maverick platform for rapid testing in doctors' offices.

People Transfer: Mar 18, 2009

Premium

Fate Therapeutics names Ken Batchelor CSO; SV Life Sciences' Ross and MedImmune Ventures' Amprey join NKT Therapeutics board

NHLBI in late January put out an RFP for the program, which calls for researchers to develop proteomics technologies and apply them to solve clinical puzzles. It is set to begin early next year, shortly after its current two major proteomics initiatives expire.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.